bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) released its earnings results on Friday. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.10) by $1.46, FiscalAI reports. The company had revenue of $1.51 million for the quarter, compared to analysts’ expectations of $1.70 million. bioAffinity Technologies had a negative net margin of 280.53% and a negative return on equity of 285.75%.
bioAffinity Technologies Price Performance
BIAF stock opened at $0.51 on Friday. bioAffinity Technologies has a one year low of $0.51 and a one year high of $13.50. The company’s fifty day moving average price is $0.93 and its 200-day moving average price is $1.64. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.34 and a current ratio of 1.36. The company has a market capitalization of $2.42 million, a PE ratio of -0.07 and a beta of -1.05.
Analyst Ratings Changes
BIAF has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday, July 20th. Wall Street Zen lowered bioAffinity Technologies from a “hold” rating to a “sell” rating in a research note on Sunday, August 2nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, bioAffinity Technologies currently has a consensus rating of “Sell”.
Institutional Trading of bioAffinity Technologies
Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC bought a new position in shares of bioAffinity Technologies during the 4th quarter valued at about $36,000. Scientech Research LLC purchased a new position in shares of bioAffinity Technologies during the third quarter valued at about $49,000. Finally, J. Safra Sarasin Holding AG bought a new stake in shares of bioAffinity Technologies in the first quarter worth about $164,000. 1.64% of the stock is currently owned by institutional investors.
bioAffinity Technologies Company Profile
bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.
The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.
Read More
- Five stocks we like better than bioAffinity Technologies
- AI Cold War Catches Light: Federal Friction in the Server Rack
- 3 Stocks Whose Charts May Be Signaling the Next Big Move
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
